Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ibrutinib and Standard Immuno-Chemotherapy (R-CHOEP-14) in Younger, High-Risk Patients With Diffuse Large B-Cell Lymphoma

NCT03399513 is registered in ClinicalTrials.gov with University Hospital Muenster as lead sponsor.

NCT NCT03399513
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03399513 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ibrutinib and Standard Immuno-Chemotherapy (R-CHOEP-14) in Younger, High-Risk Patients With Diffuse Large B-Cell Lymphoma
Lead sponsor
University Hospital Muenster
Phase
Phase 2
Overall status
Completed
Start date
May 3, 2018
Completion date
December 23, 2023
Enrollment
40 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b cell lymphoma